Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Divis, Gregory

Employees

188

Website

www.avadel.com

IPO Date

1996-06-07

Headquarters

10 Earlsfort Terrace, Dublin, Co. Dublin, D02 T380, Ireland

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Avadel Pharmaceuticals AVDL

Avadel Pharmaceuticals Earnings Call Summary

Avadel Pharmaceuticals Earnings

Transcripts

Events

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals
AVDL